The product has been launched as a subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency. It includes Immune Globulin Infusion 10% (Human) (IG 10%) and recombinant human hyaluronidase developed by Halozyme.
The US Food and Drug Administration approved the product in September 2014. University of Texas Southwestern Medical School clinical professor of paediatrics and clinical investigator on the HYQVIA clinical trial, Richard Wasserman, stated that Hyqvia will have a significant impact on the treatment of primary immunodeficiency.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia